Clinical Trial Update: Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology [NA]

View source ↗

Summary

Clinical trial update reporting continued access to WATCHMAN LAA closure in patients with atrial fibrillation; study status completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• WATCHMAN Left Atrial Appendage Closure Technology

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Atrial Fibrillation | NA | Status: COMPLETED | Results posted: 2021-11-24